Clinical Trials

A Phase 2, Study to Evaluate the Safety and Efficacy Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Uterine Fibroids

Status: Active

Purpose: To determine the safety and efficacy of two vaginal doses of Proellex in premenopausal women with symptomatic uterine fibroids confirmed by MRI.

Eligibility:

  • Otherwise healthy adult females between 18 and 47 years
  • Subject must have uterine fibroids

Study Drug: Proellex® 6mg and 12mg vaginal capsules and matching placebo

Study Design: Treatment, Double-Blind, Safety

Primary Outcome Measures:

  • Percentage of subjects who become amenorrheic after one course of treatment [ Time Frame: 6 months ] [ Designated as safety issue: No ]

For more information, please visit www.clinicaltrials.gov. If you meet the study criteria and are interested in participating, please contact:

Study Director:
Repros Therapeutics Inc.
800-895-6554ext 3401
StudyInfo@reprosrx.com

Clinical Site Locations:

Florida
Ft. Lauderdale

Georgia
Atlanta

Kansas
Wichita

Louisiana
New Orleans

Michigan
Saginaw

North Carolina
Raleigh

Texas
Houston

Virginia
Richmond

2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax